ESMO 2025

Questions discussed in this category

What are your top takeaways in Gyn Cancers from ESMO 2025?

1 Answer available

What are your top takeaways in Breast Cancer from ESMO 2025?

7 Answers available

What are your top takeaways in GI Cancers from ESMO 2025?

1 Answer available

What are your top takeaways in thoracic cancers from ESMO 2025?

1 Answer available

What are your top takeaways in GU Cancers from ESMO 2025?

4 Answers available

Papers discussed in this category

N Engl J Med, 2022 Jan 19

Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.

Lancet (London, England), 2025 Jun 02

Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial.

Journal of gynecologic oncology, 2025 Jul

Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma: the Asian cohort of the AtTEnd/ENGOT-EN7 trial.

The Lancet. Oncology, 2022 Jun 09

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial.

Annals of oncology : official journal of the European Society for Medical Oncology, 2025 Oct 18

Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase 3 trial.

The New England journal of medicine, 2025 Oct 19

Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer.

Future oncology (London, England), 2023 Aug 01

TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer.

J. Clin. Oncol., 2020 Sep 20

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).

The New England journal of medicine, 2024 Mar 21

Ribociclib plus Endocrine Therapy in Early Breast Cancer.

The New England journal of medicine, 2025 May 31

Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer.

The New England journal of medicine, 2025 Oct 29

Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer.

The New England journal of medicine, 2025 Oct 20

ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer.

The New England journal of medicine, 2025 Oct 19

Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer.

Lancet Oncol, 2021 Mar 12

Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.

Future oncology (London, England), 2025 Nov 13

BREAKWATER Phase III: results for encorafenib and cetuximab plus mFOLFOX6 in first-line V600E-mutant metastatic colorectal cancer.

Lancet (London, England), 2025 Oct 20

Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial.

J Clin Oncol, 2019 Jun 02

Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study.

The New England journal of medicine, 2025 Oct 19

Sacituzumab Tirumotecan in EGFR-TKI-Resistant, -Mutated Advanced NSCLC.

Annals of oncology : official journal of the European Society for Medical Oncology, 2025 Oct 17

\zaAlectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: Final overall survival analysis of the Phase III ALEX study.

Related Topics